anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIM: To compare the effectiveness of artificial neural network (ANN) and traditional statistical analysis on identical data sets within the splenectomy-middle carotid artery occlusion (MCAO) mouse model.
METHODS: Mice were divided into the splenectomized (SPLX) and sham-operated (SPLX-sham) group. A splenectomy was conducted 14 days before middle carotid artery occlusion (MCAO). Magnetic resonance imaging (MRI), bioluminescent imaging, neurological scoring (NS), and histological analysis, were conducted at two, four, seven, and 28 days after MCAO. Frequentist statistical analyses and ANN analysis employing a multi-layer perceptron architecture were performed to assess the probability of discriminating between SPLX and SPLX-sham mice.
RESULTS: Repeated measures ANOVA showed no significant differences in body weight (F (5, 45)=0.696, P=0.629), NS (F (2.024, 18.218)=1.032, P=0.377) and brain infarct size on MRI between the SPLX and SPLX-sham groups post-MCAO (F (2, 24)=0.267, P=0.768). ANN analysis was employed to predict SPLX and SPL-sham classes. The highest accuracy in predicting SPLX class was observed when the model was trained on a data set containing all variables (0.7736±0.0234). For SPL-sham class, the highest accuracy was achieved when it was trained on a data set excluding the variable combination MR contralateral/animal mass/NS (0.9284±0.0366).
CONCLUSION: This study validated the neuroprotective impact of splenectomy in an MCAO model using ANN for data analysis with a reduced animal sample size, demonstrating the potential for leveraging advanced statistical methods to minimize sample sizes in experimental biomedical research.
Bosentan was administered at 4 mg/kg twice daily (b.i.d.) until the end of the study. It could be down-titrated to 2 mg/kg b.i.d. if not well tolerated.
Subjects will conduct SoCIAL programme once a week, for a total of 10 weeks. Every session consists of two different modules: 1) a training programme that helps patients recognize emotions and important social signals (such as facial expressions and prosody) and develop strategy focused on the Theory of Mind; 2) a training in narrative enhancement. Time of administration for both modules is 30 minutes; the operator, however, can choose to focus the session on one module rather than the other, based on the subject's specific needs.
The mitochondrion is an essential cell organelle known as the powerhouse of the cell. Mitochondrial ribosomal proteins (MRPs) are nuclear encoded, synthesised in the cytoplasm but perform their main functions in the mitochondria, which includes translation, transcription, cell death and maintenance. However, MRPs have also been implicated in cancer, particularly advanced disease and metastasis across a broad range of cancer types, where they play a central role in cell survival and progression. For some, their altered expression has been investigated as potential prognostic markers, and/or therapeutic targets, which is the focus of this review. Several therapies targeting MRPs are currently approved by the Food and Drug Administration and the European Medicines Agency for use in other diseases, revealing the opportunity for repurposing their use in advanced and metastatic cancer. Herein, we review the evidence supporting key MRPs as molecular drivers of advanced disease in multiple cancer types. We also highlight promising avenues for future use of MRPs as precision targets in the treatment of late-stage cancers for which there are currently very limited effective treatment options.
The present invention relates to traditional Chinese medicine for treating facial skin disease, which is used for treating the diseases of skin such as facial acne, facial comedos, facial freckles, facial spots, etc. The facial acne, the facial comedos, facial color spots, etc. are frequently encountered diseases of people with steatorrhea skin, particularly puberal people; the diseases repeatedly occur; the pigment is left for the people with not serious diseases; the spots are left for the people with serious diseases; facial beautification and health are seriously influenced. The medicine comprises the traditional Chinese medicine with detoxification, promoting tissue regeneration, removing wrinkles and regulating vital energy. The traditional Chinese medicine comprises detoxification traditional Chinese medicine, traditional Chinese medicine for promoting tissue regeneration, traditional Chinese medicine for removing wrinkles and traditional Chinese medicine for regulating vital energy, wherein the detoxification traditional Chinese medicine comprises 20 wt. % of dandelion, and 20 wt. % of scutellaria roots; the traditional Chinese medicine for promoting tissue regeneration comprises 10 wt. % of astragalus roots, and 10 wt. % of chuanqiong; the traditional Chinese medicine for removing wrinkles comprises 10 wt. % of schizonepeta, 10 wt. % of almond, and 20 wt. % of chrysanthemum flower; the traditional Chinese medicine for regulating vital energy comprises 10 wt. % of green tangerine peel, and 10 wt. % of fructus aurantii; the traditional Chinese medicine is powder and is made into troche, or powder or decoction according to a conventional mode. The product can treat facial acne, facial blains, surface warts, comedos and all color keloids, and the effective rate is more than 97%.
FMF is a rare disease, which permanently affects daily life of the patients with severe pain and the risk of developing a life threatening amyloidosis. Today there are only very limited treatment options and an ongoing highly unmet medical need for improved treatment strategies. This study will be the first randomized, controlled trial to assess the benefit as well as the safety profile of IL6 receptor inhibition wirth TCZ in patients with FMF. Elevated tissue and serum levels of IL-6 have been implicated in the pathogenesis of FMF. FMF attacks are painfull during the period of the attack but are not life- or organthreatening and usually can be handeled by nonsteroidal and antipyretic treatment. Amyloidos is a longtime complication that appears after several years of uncontrolled disease. Placebo control trials' data are characterized as having greater ability to distinguish between effective and ineffective treatments (that is, greater assay sensitivity). The concerns about placebo use should revolve around the issue of risk to participants, rather than around denial of treatment, and that in the absence of a significant risk of harm, placebo treatment is acceptable. In general, it is easier to achieve statistical significance in placebo-controlled trials, where effects tend to be larger, such that smaller numbers of participants need to be exposed to the investigational medication (and research costs are lower.) This is especially important in rare diseases like FMF. If an active control was itself never evaluated in a placebo-controlled trial, using it in an equivalency study, begs the question of its efficacy. This is the case for Canakinumab as a potential active comparator in FMF. No randomized controlled trial is published for this indication by now. Therefore, a placebo controlled study over a period of 16 weeks seems to be justifiable without exposing our patients to risk of serious or irreversible harm. NSAR and antipyretic treatment, as a rescue therapy for attacks, is possible throughout the study. In addition, all patients with uncontrolled active disease despite NSAR or paracetamol will drop out and will be treated with escape therapy, especially Canakinumab. Based on the available safety data in the RA program, the adverse effects of TCZ have been shown to be manageable (e.g. cytopenia, liver encyme elevation), reversible and usually not treatment limiting . The safety profile and tolerability of TCZ are expected to be similar or even better in patients with FMF than in patients with rheumatoid arthritis or giant cell arteritis, as the cohort of FMF patients is, in general, younger and shows less concomitant diaseases. Overall, the benefit-risk ratio of FMF patients to be treated with TCZ is judged positive.
This study is a randomized, double-blind, placebo-controlled trial to evaluate the effects of 400 mg albendazole treatment against placebo on the incidence of diarrheal disease caused by viral and bacterial pathogens in school children in southern Vietnam. Children will be enrolled from three primary schools in Cu Chi district in Ho Chi Minh City, Vietnam. Children will be screened for infections by the four most common soil-transmitted helminths, Ascaris lumbricoides, Trichuris trichiura, Necator americanus, and Ancylostoma duodenale. Infected and uninfected individuals will be recruited into the study and randomized to either receive albendazole treatment once every three months for 12 months, or to placebo once every three months for 9 months, after which albendazole treatment will be given at month 12, in accordance with the current deworming schedule in Cu Chi district. A questionnaire regarding the participant's demographics, his/her daily habits, and potential sources of infection will be administered at baseline. Weekly active and passive surveillance of diarrheal cases will be conducted throughout the study, and a health questionnaire will be administered during all cases of diarrhea and at the end of the study.
PURPOSE: To obtain a controlled release pharmaceutical composition in an oral unit administration form by filling a capsule with active spherical granules comprising an active carbonic anhydrase-inhibiting factor medicine, a diluent for forming a matrix in which the medicine is dispersed, and arbitrarily a vehicle. CONSTITUTION: This controlled release pharmaceutical composition comprises an active carbonic anhydrase-inhibiting factor medicine (e.g. methazolamide), a diluent solid at the ordinary temperature and suitable for forming medicine- dispersed matrix, preferably fine crystalline cellulose, and, if necessary, a pharmaceutically acceptable vehicle. The components are mixed by a mixer. The mixture is granulated in the presence of a granulating liquid, and the granules are extruded and subsequently sphered to form the spherical granules capable of being compressed. The spherical granules are dried, filled into a capsule having a hard or soft outer shell in the therapeutically effective number. If necessary, the capsule is sealed.
A novel treatment for dialysis patients needing a hemodialysis graft by providing a therapeutic formulation that can be infused to such patients, which may mitigate graft-related neointimal hyperplasia, thrombosis, and/or related mechanisms of graft failure. The therapeutic formulation may include sirolimus and/or other olimus drug(s). The therapeutic formulation may be infusible and stable in solution for such a pharmaceutical and therapeutic purpose. The therapeutic formulation may have a pharmaceutically acceptable shelf life such that the pharmaceutical agent remains chemically stable (e.g., does not precipitate) for a suitable number of days (e.g., at least 30 days, at least 60 days, at least 90 days, etc.) at 37° C. The therapeutic formulation may be suitable for application to a patient's blood vessel/vascular graft via an infusion pump. For instance, the therapeutic formulation may be suitable for application to the patient's hemodialysis graft location.
FIELD: medicine, stomatology, pharmacy. SUBSTANCE: invention relates to agents used in treatment of inflammatory diseases of parodontium. Agent comprises thymol, phenylsalicylate, eugenol, clove oil, sage oil, peppermint oil, sodium fluoride and accessory substances being components are taken in the definite quantitative ratio. Agent elicits the expressed bactericidal, antiseptic, analgetic and refreshing effect. EFFECT: valuable medicinal properties of agent. 1 ex
FIELD: biotechnology. SUBSTANCE: invention relates to new compounds named as "leistroduxins" with the corresponding structural formula. Leistroduxins and their salts can be obtained by fermentation of microorganisms of genus Streptomyces, in part, Streptomyces platensis, strain FEPM BP-3288. Leistroduxins can be used for treatment and prophylaxis of unfavorable responses as result of chemotherapy or radiotherapy of cancer, infections, cerebral disorders and fungal infections. EFFECT: enhanced effectiveness of agent. 8 cl, 1 tbl
BACKGROUND: Evidence supporting anticoagulation with unfractionated heparin (UFH) in patients with an intra-aortic balloon pump (IABP) to prevent limb ischaemia remains limited, while bleeding risks remain high. Monitoring heparin in this setting with anti-factor Xa (anti-Xa) is not previously described.
OBJECTIVES: The study objective is to describe the incidence of thromboembolic and bleeding events with the use of UFH in patients with an IABP utilising monitoring with both anti-Xa and activated partial thromboplastin time (aPTT).
METHODS: This is a retrospective study of adults who received an IABP and UFH for ≥24 hours. Electronic medical records were reviewed for pertinent data. The primary outcome was the incidence of limb ischaemia during IABP. Secondary outcomes included myocardial infarction, thrombus on IABP, or stroke. Exploratory outcomes included any venous thromboembolism and bleeding events.
RESULTS: Of 159 patients, 88% received an IABP for cardiogenic shock and median duration of IABP support was 118 hours (interquartile range, 67-196). Limb ischaemia occurred in four of 159 patients (2.5%). Strokes occurred in 3.8% of the cohort, and bleeding events occurred in 33%. Despite anticoagulation use in all patients, 11% experienced a venous thromboembolism, with most identified upon asymptomatic screening with concern for heparin-induced thrombocytopenia. We found no differences in outcomes that occurred with a hybrid anti-Xa and aPTT versus aPTT monitoring alone.
CONCLUSIONS: We observed a high rate of thrombotic and bleeding complications with the use of UFH in patients with an IABP. Use of anti-Xa versus aPTT for monitoring was not associated with complications. These data suggest safer anticoagulation strategies are needed in this setting.
This group will be given a subscription to Pandora Plus for the duration of the study. Beginning two nights before surgery, they will listen to a music playlist they created for 30 minutes prior to going to sleep. This will continue each night with the final time being 6 nights after surgery.
Submucosal invasive (T1) colorectal cancer is a significant clinical management challenge, with an estimated 10% of patients developing extraintestinal lymph node metastasis. This condition necessitates surgical resection along with lymph node dissection to achieve a curative outcome. Thus, the precise preoperative assessment of lymph node metastasis risk is crucial to guide treatment decisions after endoscopic resection. Contemporary clinical guidelines strive to identify a low-risk cohort for whom endoscopic resection will suffice, applying stringent criteria to maximize patient safety. Those failing to meet these criteria are often recommended for surgical resection, with its associated mortality risks although it may still include patients with a low risk of metastasis. In the quest to enhance the precision of preoperative lymph node metastasis risk prediction, innovative models leveraging artificial intelligence or nomograms are being developed. Nevertheless, the debate over the ideal sensitivity and specificity for such models persists, with no consensus on target metrics. This review puts forth postoperative mortality rates as a practical benchmark for the sensitivity of predictive models. We underscore the importance of this method and advocate for research to amass data on surgical mortality in T1 colorectal cancer. Establishing specific benchmarks for predictive accuracy in lymph node metastasis risk assessment will hopefully optimize the treatment of T1 colorectal cancer.
For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
Infant motor development is affected by the sociocultural context in which it takes place. Because societal and cultural practices are dynamic, this exploratory study examined whether the ages at which infants typically learned to crawl, cruise, and walk changed over the past 3 decades. We compiled archival data from 1,306 infants born between January 31, 1992, and December 10, 2021. Parents originally reported milestone onsets in interviews and by using diaries. For each motor milestone, a linear regression model predicted the onset age using birth date. Segmented regression analyses inspected changes in slopes over time. Covariates included rural/urban housing, gestation age, season of birth, and birth weight. Infants' average crawling, cruising, and walking onset ages changed over time. After controlling for the covariates, infants' crawling onset age steadily increased until 2012, after which crawling onset age decreased. Infants' cruising onset age increased from 1991 to 2001, after which cruising onset age remained stable. After controlling for the covariates, infants' walking onset increased until 2015, after which walking onset age decreased. Thus, when infants were born explained a small but significant amount of variability in infant motor skill onset. While the current study showed that motor development changed over the years, motor development is just a model system for development more generally: Cohort effects may be pervasive across developmental domains. Using motor development as a model system for studying change suggests that generational effects due to a changing society may be pervasive across developmental domains. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
Exercise is a valuable basic treatment method in the discipline of physiotherapy and rehabilitation. The importance of exercise in maintaining and improving health or in combating diseases and/or injuries has been recognized. However, exercise therapy requires care, compliance, and discipline, otherwise, it is not possible to achieve positive results from this type of treatment. Examining factors that affect adherence to exercise can help understand and resolve issues that may hinder individual participation. The planned aim of this study was to develop a questionnaire that could describe individuals' compliance with participation in a home exercise program using the Delphi method, and then analyze the psychometric validity and reliability of this questionnaire. For this reason, academic physiotherapists or physiotherapists with at least 5 years of clinical experience will be asked to identify questions and details that can assess individuals' compliance with home exercise. Based on their responses, a questionnaire with at least 10 questions will be prepared by the investigators. Then, the appropriateness of the questions of this questionnaire will be examined and presented to the expert opinions again. The participating experts will be asked to rate each item sent to them on a Likert-type scale of 1 (strongly disagree) to 5 (strongly agree) whether it should be included in the questionnaire. If there is 80% or more consensus on an item for 4 and 5, the item will be considered to have reached consensus. Once the questionnaire has been created based on the Delphi method, it will be administered as an online questionnaire to 50 volunteer participants who have been given a home exercise program within physiotherapy and rehabilitation treatment and thus the basic psychometric properties of the questionnaire (internal consistency, test-retest reliability) will be analyzed. The evaluation questionnaire planned to be obtained at the end of this study is expected to significantly contribute to the field of exercise science.
Adolescents face a higher risk for HIV, STIs, and unintended pregnancy than any other age group in sub-Saharan Africa, and have unique health care needs as they navigate this period of growth and developmental milestones. We conducted the Youth Friendly Services study among adolescents in Rustenburg, South Africa to address some of these concerns. Participants aged 12-19 were followed quarterly for 12 months, asked at baseline about demographics, their sexual behavior, and tested for HIV, STIs, and pregnancy (girls). Report of sexual activity was not a requirement for enrollment. Assent and parental consent were obtained for participants under 18. Some follow up visits fell during COVID-mandated shutdowns, and we worked with participants to reschedule and extend follow up as appropriate. Here we present data on reported behaviors, participant attrition, risk of HIV, other STI, and pregnancy. From May 2018 to August 2019, we enrolled 223 HIV-negative, non-pregnant adolescents (64% girls). The median age was 17 (IQR: 14-18). Among the 119 (53%) participants who reported being sexually active at baseline, the median age at first sex was 16 years (IQR: 15-17). During follow-up, an additional 16 (7%) participants reported having their first sexual encounter. Among the sexually active participants, the incidence of HIV was 1.5 cases / 100 person-years at risk (PYAR, 95% CI: 0.4-6.0), the incidence of chlamydia was 15.7 cases (95% CI: 10.1-24.4), gonorrhea was 4.7 cases (95% CI: 2.1-10.5), and HSV was 6.3 cases (95% CI: 3.1-12.6); we observed no cases of incident syphilis. The incidence of pregnancy among sexually active girls was 15.0 pregnancies / 100 PYAR (95% CI: 8.5-26.5). Despite small numbers, the incidence of most STIs was significantly higher in females compared to males. We also observed two pregnancies and 5 incident STIs among participants who reported never having had sex, these tended to be younger participants. From March to September 2020, the clinic was shut down for COVID-19, and 53 study visits were postponed. Follow up was concluded in November 2020, a total of 19 participants were lost to follow up, however only one participant dropped off-study during COVID-19 shutdowns. Retention at the final visit was 91.5%. We successfully completed a prospective study of adolescents to learn more about the risks they face as they navigate sexual debut in the context of a program of youth-friendly counseling and services. Among self-reported sexually active participants, we observed a high rate of HIV, STI and pregnancy, however we also observed pregnancy and STIs among those who reported no sexual activity.
Disclosed is a therapeutic or prophylactic agent for diabetes, which contains a thiazolidine derivative that is a PPAR-? agonist as an active ingredient, and which is reduced in the side effects of PPAR-? agonists. Specifically disclosed is a therapeutic or prophylactic agent for diabetes, which contains a specific IP agonist such as beraprost sodium (BPS) and a thiazolidine derivative such as pioglitazone or a pharmacologically acceptable salt thereof. The therapeutic or prophylactic agent exhibits sufficiently effective hypoglycemic action without being accompanied by characteristic side effects of PPAR-? agonists (such as weight gain), and is useful as a highly safe and highly effective therapeutic or prophylactic agent for diabetes.